Yahoo Finance 
Covid Vaccine: What The EU Row With AstraZeneca Means For The UK
A row between the EU and coronavirus vaccine manufacturer AstraZeneca has prompted fears supplies could be disrupted within the bloc, as well as to the UK.
The European Commission has threatened to impose tight controls on the export of vaccines made in the bloc, potentially impacting the UK’s supply of Pfizer jabs.
This is what you need to know:
What prompted the row?
The EU is currently involved in a dispute with AstraZeneca, which makes the Oxford vaccine, over delays to deliveries of the jab.
The bloc has accused the company of a “lack of clarity” and “insufficient explanations” after it said it cannot meet agreed supply targets up to the end of March.
EU health commissioner Stella Kyriakides said “the answers of the company have not been satisfactory so far,” following a meeting on Monday.
The EU wants to know exactly which doses have been produced where by @AstraZeneca so far, and if, or to whom, they have been delivered.
The answers of the company during the Steering Board discussion have not been satisfactory so far. A second meeting is scheduled for tonight.— Stella Kyriakides (@SKyriakidesEU) January 25, 2021
An EU official involved in the talks told Reuters that meant a 60% cut to 31 million doses, a blow to the bloc which was already facing criticism for lagging the United States and Britain with its vaccination campaign.
The EU has asked AstraZeneca to find flexible ways to deliver doses and urged it to disclose vaccine production and distribution data.
How has the EU responded?
EU health commissioner Stella Kyriakides has proposed forcing drugmakers to register in advance their Covid-19 vaccine exports, so the bloc can keep track of what they are doing.
She further warned the EU “will take any action required to protect its citizens and rights”, adding: “In the future, all companies producing vaccines against Covid-19 in the EU will have to provide early notification whenever they want to export vaccines to third countries.”
On...
